Clene Inc Dossier - Source-backed chat

Clene Inc

CLNNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.02Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $57.1M

Enterprise Value $65.1M

Shares Outstanding 12.7M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Clene Inc. is a late clinical-stage biopharmaceutical company pioneering clean-surfaced nanotechnology (CSN) therapeutics. The investment thesis centers on its lead asset, CNM-Au8, an oral suspension of gold nanocrystals targeting mitochondrial dysfunction in neurodegenerative diseases. Following a constructive Type C meeting, the FDA indicated that Clene's neurofilament light (NfL) biomarker data may support an NDA submission under the Subpart H accelerated approval pathway for ALS. This regulatory pivot significantly de-risks the near-term path to market, with an NDA filing planned for Q3 2026. While the company faces substantial going concern risks and ongoing cash burn, recent capital injections—including a $28 million milestone-linked registered direct offering and a $7 million underwritten offering—provide a bridge to key regulatory catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$32.20

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA issues a Refusal to File or a Complete Response Letter (CRL) demanding complete Phase 3 data prior to approval. Milestone-linked warrants expire unexercised, and the company is unable to raise additional capital, triggering its going concern warning and forcing a severe curtailment of operations.

Base CaseCentral scenario

The FDA accepts and reviews the CNM-Au8 NDA under the accelerated approval pathway based on NfL biomarker data. Clene successfully initiates its Phase 3 confirmatory trial in Q1 2027. Milestone-linked warrant tranches are exercised, providing over $22 million in additional capital to extend the cash runway into 2027 and support commercial launch preparations.

Bull CaseUpside scenario

Successful Phase 3 RESTORE-ALS trial validation and subsequent FDA accelerated approval of CNM-Au8, driving exponential revenue growth and establishing Clene as a prime acquisition target for larger biopharma companies.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA alignment on an accelerated approval pathway for CNM-Au8 in ALS using NfL as a surrogate endpoint.
First-in-class catalytic mechanism of action targeting cellular energy failure, applicable across multiple high-value neurodegenerative indications (ALS, MS, Parkinson's).
Structured milestone-linked financing that mitigates near-term cash runway risks upon positive regulatory progress.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern without securing additional funding.
High risk of equity dilution from outstanding warrants, convertible notes, and future capital raises.
Regulatory uncertainty inherent in surrogate endpoint-based accelerated approvals.

Thesis Invalidation Triggers

FDA rejection or Refusal to File the NDA for CNM-Au8 in ALS.
Failure to maintain the minimum $2.0 million unrestricted cash covenant under senior secured notes.
Inability to initiate the Phase 3 confirmatory trial by Q1 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.